• Zoledronic acid maintains BMD gains after overlapping teriparatide, denosumab treatment

    5 days ago - By Healio

    A single dose of zoledronic acid effectively maintains large and rapid gains in spine and hip bone mineral density after 15 months of overlapping teriparatide and denosumab therapy, according to a speaker.
    The cessation of denosumab leads to prompt bone loss, loss of antifracture efficacy and increased risk for multiple vertebral fractures, Sabashini K. Ramchand, MD, research fellow in medicine in the department of endocrinology at Massachusetts General Hospital, said during an online presentation at the virtual American Society for Bone and Mineral Research Annual Meeting.
    Read more ...